Key Highlights
- Moderna shares rose approximately 2.87 percent in pre-market trading to $60.87, extending last week's post-earnings rally.
- The FDA approved mFLUSIVA, Moderna's first mRNA based seasonal flu Vaccine and its fourth approved product overall.
- The move builds on second quarter 2026 results showing a narrower than expected net loss of $1.97 per share and Revenue of $145 million that beat estimates.
- Wall Street sentiment remains cautious, with a consensus Reduce rating and an average price target of $42.13, well below current trading levels.
Flu Vaccine Approval Expands Respiratory Portfolio
Moderna, Inc. ( Nasdaq :MRNA), a biotechnology company known for pioneering mRNA based medicines including its widely distributed COVID-19 vaccine, traded higher in pre-market activity as investors responded to the FDA's approval of mFLUSIVA. The approval marks the company's first mRNA based seasonal flu vaccine and its fourth approved product overall, expanding its respiratory portfolio ahead of the 2026 to 2027 flu season.
Approval Builds on Strong Earnings Momentum
The move builds on momentum from Moderna's second quarter 2026 results, reported the prior week, which showed a narrower than expected net loss of $1.97 per share and revenue of $145 million that beat estimates. The company also reiterated full-year guidance and lowered cost and R&D guidance, reflecting Manufacturing efficiency gains.
Wall Street Remains Cautious Despite the Rally
Despite the positive momentum, Wall Street sentiment remains cautious, with a consensus Reduce rating and an average price target of $42.13, well below current trading levels. Insiders sold roughly $5.9 million in shares over the quarter, suggesting some disconnect between near-term price action and longer-term analyst views.
Conclusion
Moderna's pre-market gain reflects tangible regulatory progress layered onto an already improving earnings trajectory, with mFLUSIVA giving the company a new commercial product just ahead of peak flu season. The gap between the stock's rally and Wall Street's cautious consensus suggests the market may be pricing in a more optimistic outlook than analysts have yet incorporated.






Please wait processing your request...